IL21R and colitis: Like human IBD, mice with acute DSS-colitis and TNBS-relapsing colitis produce elevated levels of IL-21, and administration of a neutralizing IL-21R fusion protein to DSS-treated mice attenuates the ongoing colitis and reduces the production of Th17-related cytokines [60].